Selecting the right virtual care partner is now one of the most consequential decisions a health plan can make. The market is crowded with more than 13,000 digital health companies, and the differences between them are rarely obvious. To cut through the noise, payers need a disciplined, evidence‑driven approach to vendor evaluation for virtual care, Remote Patient Monitoring (RPM), and telehealth that separates true clinical and operational value from marketing claims.
This guide provides a comprehensive virtual care vendor checklist for payers, including compliance requirements, clinical evidence standards, ROI methodology, and the deal‑breakers that should immediately disqualify a vendor.
The digital health ecosystem now includes roughly 13,000 vendors, spanning telehealth, RPM, chronic condition management, behavioral health, and AI‑driven care navigation. Many sound similar. Few are meaningfully differentiated. This makes virtual care vendor selection significantly more complex.
In 2023, the ICER‑PHTI Assessment Framework for Digital Health Technologies became the first independent, payer‑aligned standard for evaluating digital health solutions. PHTI has already published assessments on:
Payers increasingly use this framework to guide payer virtual care RFP scoring and procurement decisions.
NCQA and CMS continue to evolve HEDIS and Stars requirements, including:
Choosing the wrong vendor is no longer just a missed opportunity. It’s a Stars problem.
Evaluating a virtual care vendor requires more than reviewing features or comparing price sheets. Health plans need a structured, outcomes‑oriented framework that reveals whether a vendor can deliver measurable clinical impact, reduce total cost of care, support Stars improvement, and scale across diverse populations. The nine domains below form a comprehensive scorecard payers can use to assess vendor readiness, risk, and long‑term strategic fit. Each domain reflects the core capabilities that determine whether a virtual care partner can perform at payer scale.
|
Domain |
What to Evaluate |
Why It Matters |
|
Clinical quality |
Evidence strength, clinical protocols, outcomes data, care pathways |
Determines whether the vendor can reliably improve health outcomes and meet payer quality benchmarks |
|
Cost and utilization impact |
Avoidable ED visits, readmissions, chronic condition control, ROI methodology |
Shows whether the solution reduces total cost of care and supports value‑based performance |
|
Health equity |
SDOH data integration, multilingual support, device accessibility, inclusive design |
Ensures equitable access and aligns with NCQA and CMS equity‑focused measures |
|
Patient experience |
Engagement rates, adherence, usability, satisfaction, care navigation |
Drives adoption, retention, and downstream clinical outcomes |
|
Clinician experience |
Workflow integration, burden reduction, alert fatigue management, clinical decision support |
Determines whether clinicians will actually use and trust the platform |
|
Interoperability |
EHR integration, FHIR support, API maturity, data normalization |
Enables seamless data exchange and reduces administrative friction |
|
Security |
HITRUST, SOC 2, HIPAA, encryption, access controls |
Protects PHI, reduces risk, and meets payer‑level security requirements |
|
Regulatory |
FDA Class II clearance, 21 CFR Part 11, state licensure, audit readiness |
Ensures compliance with federal and state requirements for digital health |
|
Scalability |
Multi‑state operations, device logistics, staffing model, enterprise support |
Confirms the vendor can grow with the plan and support large populations |
If a vendor is not HITRUST r2 certified, they are not ready for payer‑level security requirements: e1 and i1 are not sufficient. When evaluating a virtual care vendor’s security posture, payers should treat HITRUST r2 as the gold standard. The e1 and i1 assessments only validate whether basic or intermediate cybersecurity controls are implemented, but they do not assess organizational maturity, governance, or the ability to manage high‑risk PHI environments.
A virtual care vendor without peer‑reviewed clinical evidence is asking a payer to take on unnecessary risk. Case studies, testimonials, and vendor‑funded white papers are marketing assets, not scientific validation. They cannot confirm whether outcomes are real, reproducible, or statistically meaningful across diverse populations. Peer review is the only mechanism that forces a vendor’s claims to withstand independent scrutiny, validated methodologies, and transparent reporting standards. Without it, payers have no reliable way to assess safety, efficacy, or equity impact, and no assurance that the vendor can influence HEDIS, Stars, or total cost of care. In a market where thousands of digital health companies make similar promises, the absence of peer‑reviewed evidence signals immaturity, unproven clinical rigor, and elevated operational and reputational risk. For any high‑stakes program, this should be a non‑negotiable exclusion criterion within clinical quality.
When a vendor “just sends data,” the burden of interpreting that data, triaging risk, closing care gaps, and managing clinical escalation shifts entirely to the plan’s internal teams. This model rarely improves outcomes because raw data does not change behavior, guide treatment, or support HEDIS and Stars performance. Without a clinical layer, there is no care protocol, no accountability for intervention, no documentation trail, and no mechanism to ensure that high‑risk members receive timely outreach. A vendor without a clinical layer cannot deliver measurable quality improvement, reduce utilization, or support value‑based care. This should be an automatic exclusion criterion within clinical quality
If you want to go deeper into how virtual care models differ, explore: Virtual Care vs. Telehealth vs. Telemedicine
And for a broader view of payer‑grade virtual care strategy, you can also visit: Virtual Care for Health Plans